{"id":800969,"date":"2025-01-15T08:06:37","date_gmt":"2025-01-15T13:06:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/"},"modified":"2025-01-15T08:06:37","modified_gmt":"2025-01-15T13:06:37","slug":"evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/","title":{"rendered":"Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>Trial remains on track for completion and data readout in the second half of 2025<\/strong><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">COPENHAGEN, Denmark, January 15, 2025 &#8211; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, has now completed the dosing of all 16 patients in its phase 2 trial with the company\u2019s lead asset EVX-01. Designed with Evaxion\u2019s AI-Immunology\u2122 platform, EVX-01 is a personalized cancer vaccine being developed as a treatment of advanced melanoma (skin cancer).<\/p>\n<p align=\"justify\">Dosing has been completed according to trial protocol and timelines, meaning the trial remains on track for completion and data readout in the second half of 2025. Coincidently, the first patient has now completed the trial and has had last visit according to the protocol. Patients will continue to be monitored and data collected.<\/p>\n<p align=\"justify\">\u201cWe are happy to report completion of the dosing in this important trial, demonstrating our strong capabilities in trial execution. Now we focus on carrying the trial through to completion and we are eagerly anticipating the full clinical data readout later this year. Based on the impressive data generated so far, we see that EVX-01 could potentially become a new and effective treatment option for advanced melanoma. With more than 300,000 new melanoma cases each year and significant medical needs, this offers great commercial potential for Evaxion\u201d, says Christian Kanstrup, CEO of Evaxion.<\/p>\n<p align=\"justify\">EVX-01 is designed with Evaxion\u2019s AI-Immunology\u2122 platform and tailored to target the unique tumor profile and immune characteristics of each individual patient. It engages the patient&#8217;s immune system to fight off cancer by mounting a targeted response against tumors.<\/p>\n<p align=\"justify\">The phase 2 trial investigates EVX-01 in combination with MSD\u2019s (Merck &amp; Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA\u00ae (pembrolizumab) in patients with advanced melanoma (skin cancer). Each patient enrolled in the trial has received a unique vaccine designed and manufactured based on their individual biology.<\/p>\n<p align=\"justify\">\n        <strong>Convincing one-year phase 2 data<\/strong><br \/>\n        <br \/>Convincing interim one-year data from the trial was presented at the European Society for Medical Oncology (ESMO) Congress in September 2024. Data demonstrated a 69% Overall Response Rate, reduction in tumor target lesions in 15 out of 16 patients, and a positive correlation between the AI-Immunology\u2122 platform predictions and immune responses induced by the individual neoantigens in the EVX-01 vaccine (p=0.00013). Further, 79% of EVX-01\u2019s vaccine targets triggered a targeted immune response, which compares very favorably to what is seen with other approaches.<\/p>\n<p align=\"justify\">\n        <strong>About EVX-01<\/strong><br \/>\n        <br \/>EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancers. It is Evaxion\u2019s lead clinical asset.<\/p>\n<p align=\"justify\">EVX-01 is a personalized therapy designed with our AI-Immunology\u2122 platform and is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient&#8217;s immune system to fight off cancer by mounting a targeted response against tumors.<\/p>\n<p align=\"justify\">In the completed Phase 1\/2a clinical trial (NCT03715985), assessing EVX-01 in combination with a PD-1 inhibitor, eight of twelve metastatic melanoma patients (67%) had objective clinical responses with two complete and six partial responses.<\/p>\n<p align=\"justify\">In addition, vaccine-induced T cells were detected in all patients and a significant correlation between clinical response and the AI-Immunology\u2122 predictions was observed, underlining the predictive power of the platform.<\/p>\n<p align=\"justify\">KEYTRUDA\u00ae is a registered trademark of Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA.<\/p>\n<p align=\"justify\">\n        <strong>Contact information<\/strong>\u00a0<br \/>Evaxion Biotech A\/S<br \/>Mads Kronborg<br \/>Vice President, Investor Relations &amp; Communication<br \/>+45 53 54 82 96<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9bW59OPcNldS_M1DjSehiH8XFXrkHq6031y6lgpNxYuQOTaTB7WW-2fYfvAlySltxpHS67hveVnHF-H6dSuxOA==\" rel=\"nofollow\" target=\"_blank\">mak@evaxion.ai<\/a>\u00a0<\/p>\n<p align=\"justify\">\n        <strong>About EVAXION<\/strong><br \/>\n        <br \/>Evaxion Biotech A\/S is a pioneering TechBio company based upon its AI platform, AI-Immunology\u2122. Evaxion\u2019s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology\u2122, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients\u2019 lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology\u2122 platform and vaccine pipeline, please <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SfOD6EJXMjz0Kpe2Brx3UgLNV1rR25R8fy0-O0wlhnCOWlSh6dQRE_gMU2VHfq88cZ1Z3Xam-rscUe8McG96mX_L8w1tZfDyBhUWM9IQW3w=\" rel=\"nofollow\" target=\"_blank\">visit our website<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-looking statement<\/strong>\u00a0<br \/>This\u00a0announcement contains forward-looking statements\u00a0within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.\u00a0The words\u00a0\u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201chope,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201canticipate,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d and other words and terms of similar meaning\u00a0identify forward-looking statements.\u00a0Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares,\u00a0the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our\u00a0business from other significant geopolitical and macro-economic events;\u00a0and other uncertainties affecting our business operations and financial condition.\u00a0For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F\u00a0and other filings\u00a0with the U.S. Securities and Exchange Commission (SEC), which are available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2_7S0H2FrKnCMq5EUvaXJ8jGPN-XZtkx0GoAySjrQV7YG5TQvemcNUh_HcgqVIqny78m513aMhRX1qnRxxd9cvqidkk_44TJ92TiIl85V3yV7QmgZVNXxacrTrszoYieGPPy5pVJcuo7M738UO1uT0mqRiL0F8Gx4UCqqPf2twHDy8YmFGo_3x3qJh24EBfIG99_XgiJm8bf0fXIqOcEphgJJE_4eOmZrsxJ-WYG4tQ=\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>.\u00a0We do not assume any obligation to update any forward-looking statements except as required by law.\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0MzIyMCM0MDIwNDU0ODYjMjI1MjA4Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/ZDgzNzZmNWItODAwNS00NGZiLTllYTgtZjFkYmEwNTVjZGRhLTEyNjM2NDA=\/tiny\/Evaxion-Biotech.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Trial remains on track for completion and data readout in the second half of 2025 COPENHAGEN, Denmark, January 15, 2025 &#8211; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, has now completed the dosing of all 16 patients in its phase 2 trial with the company\u2019s lead asset EVX-01. Designed with Evaxion\u2019s AI-Immunology\u2122 platform, EVX-01 is a personalized cancer vaccine being developed as a treatment of advanced melanoma (skin cancer). Dosing has been completed according to trial protocol and timelines, meaning the trial remains on track for completion and data readout in the second half of 2025. Coincidently, the first patient has now completed the trial and has had last visit according &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-800969","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Trial remains on track for completion and data readout in the second half of 2025 COPENHAGEN, Denmark, January 15, 2025 &#8211; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, has now completed the dosing of all 16 patients in its phase 2 trial with the company\u2019s lead asset EVX-01. Designed with Evaxion\u2019s AI-Immunology\u2122 platform, EVX-01 is a personalized cancer vaccine being developed as a treatment of advanced melanoma (skin cancer). Dosing has been completed according to trial protocol and timelines, meaning the trial remains on track for completion and data readout in the second half of 2025. Coincidently, the first patient has now completed the trial and has had last visit according &hellip; Continue reading &quot;Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-15T13:06:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0MzIyMCM0MDIwNDU0ODYjMjI1MjA4Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01\",\"datePublished\":\"2025-01-15T13:06:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\\\/\"},\"wordCount\":950,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA0MzIyMCM0MDIwNDU0ODYjMjI1MjA4Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\\\/\",\"name\":\"Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA0MzIyMCM0MDIwNDU0ODYjMjI1MjA4Nw==\",\"datePublished\":\"2025-01-15T13:06:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA0MzIyMCM0MDIwNDU0ODYjMjI1MjA4Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA0MzIyMCM0MDIwNDU0ODYjMjI1MjA4Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/","og_locale":"en_US","og_type":"article","og_title":"Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01 - Market Newsdesk","og_description":"Trial remains on track for completion and data readout in the second half of 2025 COPENHAGEN, Denmark, January 15, 2025 &#8211; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, has now completed the dosing of all 16 patients in its phase 2 trial with the company\u2019s lead asset EVX-01. Designed with Evaxion\u2019s AI-Immunology\u2122 platform, EVX-01 is a personalized cancer vaccine being developed as a treatment of advanced melanoma (skin cancer). Dosing has been completed according to trial protocol and timelines, meaning the trial remains on track for completion and data readout in the second half of 2025. Coincidently, the first patient has now completed the trial and has had last visit according &hellip; Continue reading \"Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-15T13:06:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0MzIyMCM0MDIwNDU0ODYjMjI1MjA4Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01","datePublished":"2025-01-15T13:06:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/"},"wordCount":950,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0MzIyMCM0MDIwNDU0ODYjMjI1MjA4Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/","name":"Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0MzIyMCM0MDIwNDU0ODYjMjI1MjA4Nw==","datePublished":"2025-01-15T13:06:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0MzIyMCM0MDIwNDU0ODYjMjI1MjA4Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0MzIyMCM0MDIwNDU0ODYjMjI1MjA4Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/800969","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=800969"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/800969\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=800969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=800969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=800969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}